Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Newborn Brain Assessment - CergenX Wave (NBT)

6. november 2026 opdateret af: CergenX Limited

Determining Grade of Neonatal Encephalopathy - Agreement Between the Modified Sarnat Examination and Automated AI Assessment of Newborn Brain Function Using Wave Software

In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.

A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.

The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Anslået)

165

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • Ikke rekrutterer endnu
        • University of Texas Southwestern Medical Center
        • Kontakt:
    • Cork
      • Cork, Cork, Irland
        • Rekruttering
        • Cork University Maternity Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

8 måneder og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Infants at high-risk of Neonatal Encephalopathy

Beskrivelse

Inclusion Criteria:

  1. Infants born at ≥36+0 weeks gestational age

  2. Informed consent obtained AND

  3. A pH of ≤7.0 or base deficit ≥16 (on cord or 1st infant blood gas at < 1 hour of life) OR

  4. a) A pH of 7.01-7.15 or base deficit of 10-15.9 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:

    • An APGAR score ≤5 at 10 minutes OR

    • Prolonged resuscitation (infant receiving IPPV at ≥10 minutes of life) OR

    • An acute perinatal event:

      • Abnormal CTG (variable/late foetal HR decelerations)
      • Foetal bradycardia
      • Prolapsed/ruptured/tight nuchal cord
      • Shoulder dystocia
      • Uterine rupture
      • Maternal haemorrhage/placental abruption
      • Maternal trauma (e.g. vehicle accident)
      • Mother received CPR

Exclusion Criteria:

  1. Infants < 36 weeks gestation
  2. No parental/guardian consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Neonates

Neonates at risk of Neonatal Encephalopathy

The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.

Andre navne:
  • eego amplifier

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life
Tidsramme: From the enrolment and up to 6 hours after birth
From the enrolment and up to 6 hours after birth

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.
Tidsramme: From enrolment of the participant and up to 30 hours after birth
From enrolment of the participant and up to 30 hours after birth
Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.
Tidsramme: From enrolment of the participant and up to 30 hours after birth
From enrolment of the participant and up to 30 hours after birth
Association between CergenX Wave software and clinical variables including discharge diagnosis
Tidsramme: From enrolment of the participant and up to 30 hours after birth

Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses

From enrolment of the participant and up to 30 hours after birth
Assessment of healthcare professional (device users) satisfaction with usability of the device.
Tidsramme: From enrolment of the participant and up to 30 hours after birth

An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale.

From enrolment of the participant and up to 30 hours after birth

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. oktober 2026

Primær færdiggørelse (Anslået)

1. oktober 2027

Studieafslutning (Anslået)

1. oktober 2027

Datoer for studieregistrering

Først indsendt

10. september 2026

Først indsendt, der opfyldte QC-kriterier

28. september 2026

Først opslået (Faktiske)

5. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 25116
  • DT 2023 0435 (Andet bevillings-/finansieringsnummer: Department of Enterprise, Tourism and Employment. Enterprise Ireland)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .